The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Effect of Antiviral Treatment With Nucleotide/Nucleoside Analogs on Postoperative Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma: A Two-Stage Longitudinal Clinical Study
Open accessAbstract
Purpose: Postoperative prognosis of hepatitis B virus (HBV) –related hepatocellular carcinoma (HCC) is poor. The effect of nucleotide/nucleoside analog (NA) treatment on the prognosis has not been fully clarified. Patients and Methods: We carried out a two-stage longitudinal study that included a randomized clinical trial (RCT) to evaluate the effect of NA treatment on postoperative prognosis of HBV-HCC. Seven hundred eighty patients (163 in the RCT) were enrolled onto this study following radical hepatectomy. Lamivudine, adefovir dipivoxil, or entecavir were postoperatively administered to antiviral groups. Surgical specimens were examined immunohistochemically for carboxylic acid–terminal truncated HBV X protein (Ct-HBx). Results: In the nonrandomized cohort, high viral load (≥ 10 4 copies/mL) significantly predicted unfavorable overall survival and recurrence-free survival (RFS), whereas antiviral treatment significantly improved both types of survival. In the RCT, antiviral treatment significantly decreased HCC recurrence and HCC-related death, with hazard ratios (HRs) of 0.48 (95% CI, 0.32 to 0.70) and 0.26 (95% CI, 0.14 to 0.50), respectively, in multivariate Cox analyses. Patients who received antiviral treatment had significantly decreased early recurrence (HR, 0.41; 95% CI, 0.27 to 0.62) and improved liver function 6 months after surgery compared with the controls (P < .001). Those with recovered liver function had a higher 2-year RFS rate than those without (P = .003). Ct-HBx expression in adjacent hepatic tissues significantly predicted an unfavorable RFS in the antiviral group (P < .001). Conclusion: Although it might not affect the HCC-promoting potential of Ct-HBx, NA treatment is effective in normalizing liver function, decreasing HBV-HCC recurrence, and improving postoperative survival. This effect should be validated in a multicenter phase III RCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Llovet, J. M., Ducreux, M. P., Lencioni, R. A., Bisceglie, A. M. D., Dufour, J., Greten, T. F., Raymond, É., Roskams, T., Mazzaferro, V., Bruix, J., et al. (2012) · Cited by 1,488
Resection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879
Wu, C.-Y., Chen, Y.-J., Ho, H. J., Hsu, Y.-C., Kuo, K. N., Wu, M.-S., & Lin, J.-T. (2012) · JAMA · doi:10.1001/2012.jama.11975 · Cited by 818
Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma
Yang, H.-I., Yeh, S.-H., Chen, P.-J., Iloeje, U. H., Jen, C.-L., Su, J., Wang, L.-Y., Lu, S.-N., You, S.-L., Chen, D.-S., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn243 · Cited by 580
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma
Wu, J.-C., Huang, Y.-H., Chau, G.-Y., Su, C.-W., Lai, C.-R., Lee, P.-C., Huo, T.-I., Sheen, I.-J., Lee, S.-D., & Lui, W.-Y. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.07.009 · Cited by 435
Poon, D., Anderson, B. O., Chen, L.-T., Tanaka, K., Lau, W. Y., Van Cutsem, E., Singh, H., Chow, W. C., Ooi, L. L., Chow, P., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70241-4 · Cited by 410
Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy
Peng, C.-Y., Chien, R.-N., & Liaw, Y.-F. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.033 · Cited by 224
Hung, I. F. N., Poon, R. T. P., Lai, C.-L., Fung, J., Fan, S.-T., & Yuen, M.-F. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01872.x · Cited by 197
Poon, R. T.-P., Fan, S.-T., Lo, C.-M., Liu, C.-L., Ng, I. O.-L., & Wong, J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1094 · Cited by 191
Lara-Pezzi, E., Gómez-Gaviro, M. V., Gálvez, B. G., Mira, E., Iñiguez, M. A., Fresno, M., Martínez-A., C., Arroyo, A. G., & López-Cabrera, M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15887 · Cited by 182
Yin, J., Xie, J., Liu, S., Zhang, H., Han, L., Lu, W., Shen, Q., Xu, G., Dong, H., Shen, J., et al. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.399 · Cited by 147
Self-citationSze, K. M., Chu, G. K. Y., Lee, J. M. F., & Ng, I. O. (2012) · Hepatology · doi:10.1002/hep.25979 · Cited by 144
Huang, G., Lai, E. C. H., Lau, W. Y., Zhou, W., Shen, F., Pan, Z., Fu, S., & Wu, M. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318262b218 · Cited by 123
Chen, L., Zhang, Q., Chang, W., Du, Y., Zhang, H., & Cao, G. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.015 · Cited by 115
Self-citationChan, A. C. Y. (2011) · Archives of Surgery · doi:10.1001/archsurg.2011.125 · Cited by 110
Li, N., Lai, E. C. H., Shi, J., Guo, W., Xue, J., Huang, B. S., Lau, W. Y., Wu, M., & Cheng, S. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0694-z · Cited by 106
Self-citationYeh, C., So, M., Ng, J., Yang, H., Chang, M., Lai, M., Chen, T., Lin, C., Yeh, T., & Lee, W. (2010) · Hepatology · doi:10.1002/hep.23898 · Cited by 87
Ou, D., Tao, Y., Tang, F., & Yang, L. (2006) · International Journal of Cancer · doi:10.1002/ijc.22452 · Cited by 85
Yin, J., Zhang, H., Li, C., Gao, C., He, Y., Zhai, Y., Zhang, P., Xu, L., Tan, X., Chen, J., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgm301 · Cited by 76
Self-citationHuang, Y., Tong, S., Tai, A. W., Hussain, M., & Lok, A. S.-F. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.048 · Cited by 75
Liu, H., Xu, L., He, H., Zhu, Y., Liu, J., Wang, S., Chen, L., Wu, Q., Xu, J., & Gu, J. (2012) · Cancer Science · doi:10.1111/cas.12017 · Cited by 63
Huang, Y., Wang, Z., An, S., Zhou, B., Zhou, Y., Chan, H. L., & Hou, J. (2008) · Journal of Medical Virology · doi:10.1002/jmv.21117 · Cited by 54
Huang, L., Li, J., Lau, W. Y., Yan, J., Zhou, F., Liu, C., Zhang, X., Shen, J., Wu, M., & Yan, Y. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06888.x · Cited by 49
Tranchart, H., Chirica, M., Sepulveda, A., Massault, P. P., Conti, F., Scatton, O., & Soubrane, O. (2012) · World Journal of Surgery · doi:10.1007/s00268-012-1723-9 · Cited by 43
Huang, G., Yang, Y., Shen, F., Pan, Z., Fu, S., Lau, W. Y., Zhou, W., & Wu, M. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2803-7 · Cited by 41
An, H. J., Jang, J. W., Bae, S. H., Choi, J. Y., Cho, S. H., Yoon, S. K., Han, J. Y., Lee, K. H., Kim, D. G., & Jung, E. S. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06416.x · Cited by 40
Du, Y., Su, T., Ding, Y., & Cao, G. (2012) · Hepatitis Monthly · doi:10.5812/hepatmon.6031 · Cited by 32
Self-citation
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., et al. (2020) · Liver Cancer · doi:10.1159/000509424 · Cited by 800
Self-citationGuidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Zhou, J., Sun, H.-C., Wang, Z., Cong, W.-M., Wang, J.-H., Zeng, M.-S., Yang, J.-M., Bie, P., Liu, L.-X., Wen, T.-F., et al. (2018) · Liver Cancer · doi:10.1159/000488035 · Cited by 649
Metadata
- Authors
- Yin, J., Li, N., Han, Y., Xue, J., Deng, Y., Shi, J., Guo, W., Zhang, H., Wang, H., Cheng, S., & Cao, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-10-10
- Volume
- 31
- Issue
- 29
- Pages
- 3647-3655
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113535638
- Cited by
- 307
- References
- 34
- FWCI
- 19.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.